Takeda strikes US$640m deal with Enterome
French Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2155 entries already.
Entries by Thomas Gabrielczyk
EMA recommends four biologicals for market
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Innovative delivery: dual-chamber systems
As the global demand for injectables grows, so does the demand for innovative delivery systems. For lyophilised forms, dual-chamber systems offer advantages. They have been on the market since the mid-1980s, mainly for emergency or chronic medication. The systems have been developed for the convenience of the patients/caregivers, but they also offer benefits for the pharma/biotech companies in regards to low residual volume and increased API yield.
Pioneers in the synbio revolution
Is synthetic biology on the cusp of unlocking the next industrial revolution? A major roadblock is the ability to synthesise DNA for R&D in ways that are both cheap and efficient. Established players in the field believe the answer lies in miniaturising standard chemical processes and running them in parallel systems. But the new kids on the block are betting on a completely new process that involves enzymes.
Targovax reports promising disease-free survival (DFS) data
Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.
Cutting time to market for high quality therapeutics
The demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
EU set to speed up switch to bioeconomy by new action plan
Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Affimed halts trial after patient death and SAEs
Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.